Boston University has a successful record of investing in high-technology companies. These investments are carried out through the university's wholly owned venture capital fund. One of Boston University's most important investments has been in Seragen, Inc, a biotechnology company. Seragen's activities and its recent public offering of shares are described. Finally, the article sets Boston University's entrepreneurial activities in the context of the debate about the morality of universities commercializing their research.